Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia

American Journal of Psychiatry

Volumn 156, Issue 1, 1999, Pages 88-93

  Rosenheck, Robert ^a   Dunn, Lawrence ^b   Peszke, Michael ^b   Cramer, Joyce ^b   Xu, Weichun ^b   Thomas, Jonathan ^b   Charney, Dennis ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; CLOZAPINE; HALOPERIDOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEGATIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032897189     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.1.88     Document Type: Article

References (26)

1. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
2. Meltzer HY, Burnett S, Bastani B, Ramirez LF: Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41:892-897
3. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
4. Breier A, Buchanan RW, Irish D, Carpenter WT: Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44:1145-1149
5. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summertelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
6. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
7. Buchanan RW: Clozapine: efficacy and safety. Schizophr Bull 1995; 21:579-591
8. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827-832
9. Rosenheck RA, Cramer J, Xu W, Thomas J, Henderson W, Frisman LK, Fye C, Charney D, Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia: A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337:809-815
10. Meltzer HY: Clozapine: is another view valid? (editorial). Am J Psychiatry 1995; 152:821-825
11. Meltzer HY, Burnett S, Bastani B, Ramirez LF: Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41:892-897
12. Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152:183-190
13. Marder SR: Adverse effects of clozapine. J Clin Psychiatry 1996; 14:11-12
14. Miller DD, Perry PJ, Cadoret R, Andreasen NC: A two and one-half year follow-up of treatment-refractory schizophrenics treated with clozapine (abstract). Biol Psychiatry 1992; 31(March suppl):85A
15. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M: Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993; 27: 341-347
16. Conley R, Gounaris C, Tamminga C: Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biol Psychiatry 1994; 35:746-747
17. Carpenter WT Jr, Heinrichs DW, Wagnan AMI: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:578-583
18. Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT: Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res 1993; 47:47-56
19. Spitzer RL, Williams JBW, Gibbon M, First MB: User's Guide for the Structured Clinical Interview for DSM-III-R (SCID). Washington, DC, American Psychiatric Press, 1990
20. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
21. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 217-222
22. Rosenheck R, Tekell J, Peters J, Cramer J, Fontana A, Xu W, Thomas J, Henderson W, Charney D, Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia: Does participation in psychosocial treatment augment the benefit of clozapine? Arch Gen Psychiatry 1998; 55:618-625
23. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276
24. Heinrichs DW, Hanlon TE, Carpenter WT Jr: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388-398
25. Essock SM, Hargreaves WA, Covell NH, Goethe J: Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32:683-697
26. Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia: Predictors of differential response to clozapine and haloperidol. Biol Psychiatry 1998; 44:475-482